Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09POH
|
|||
| Former ID |
DIB004902
|
|||
| Drug Name |
AEG-33773
|
|||
| Indication | Diabetic neuropathy [ICD-11: 8C0Z; ICD-10: G63, G63.2] | Phase 2 | [1] | |
| Company |
Aegera Therapeutics Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Heat shock protein 70 (HSP70) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00891683) Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy. U.S. National Institutes of Health. | |||
| REF 2 | Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.